Close Menu

NEW YORK (GenomeWeb) – Enigma Diagnostics, a UK firm currently in liquidation, announced today it is selling intellectual property underlying its point-of-care molecular diagnostics platform.

The technology — which was originally created at the UK Ministry of Defence Science and Technology Laboratory — was developed by Enigma into an easy-to-use molecular diagnostics process which the firm noted has been tested in hospitals in Europe and China with accuracy rates in excess of 90 percent. It has also received £140M million ($174 million) in investments to date.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.